We cover
ASCO GU | Genitourinary Cancers Symposium
ASCO GU 2024
ASCO GU 2025
Real-World Treatment Patterns of Nivolumab + Cabozantinib Compared with Other 1L IO Combinations in mRCC
/ Cherrishe Brown-Bickerstaff / Jan Andreasen
Bone Pain as a Key Prognostic Indicator in Castration-Sensitive Prostate Cancer
/ Deniz Tural / Jan Andreasen
Real-Life Data Confirms Avelumab Maintenance Benefits in Metastatic Urothelial Carcinoma
/ Deniz Tural / Jan Andreasen
Cabozantinib Real-World Effectiveness in the Second-Line Setting of Metastatic Renal Cell Carcinoma
/ Martin Zarba / Jan Andreasen
Danish Study Reveals Doubling of Kidney Cancer Cases and a Growing Gender Gap
/ Johanne Ahrenfeldt / Jan Andreasen
ASCO GU 2024
Cancer Epigenomics Improve the Overall Survival and the Quality of Life
/ Marc Eid / Karl Semaan
Real-World Data on Avelumab as 1L Maintenance Treatment
/ Philippe Barthelemy
News from ASCO GU 2023
Meet the experts • Uro Oncology 2023 • Meet the experts
ASCO GU 2022 and 2023
Lisää uutisia ASCO GU 2021 -symposiumista
Management of Erdafitinib, a pan-FGFR kinase inhibitor, treatment-emergent adverse events
/ Arlene O. Siefker-Radtke